Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.39USD
4:16pm BST
Change (% chg)

$-0.01 (-0.42%)
Prev Close
$2.40
Open
$2.42
Day's High
$2.45
Day's Low
$2.30
Volume
7,695
Avg. Vol
12,030
52-wk High
$5.55
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED.ONCOMED PHARMACEUTICALS INC - IN INTERIM, OFFICE OF PRESIDENT WILL CONTINUE TO PERFORM DUTIES OF PRESIDENT AND CEO.ONCOMED PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED PERRY KARSEN AS CHAIRMAN OF BOARD.  Full Article

OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM.ONCOMED PHARMACEUTICALS INC - YEAR-END 2017 CASH BALANCE OF $103.1 MILLION.ONCOMED PHARMACEUTICALS INC - ‍PRESENTATION OF CLINICAL DATA ON PHASE 1 PROGRAMS EXPECTED IN 2018​.ONCOMED PHARMACEUTICALS - CURRENT CASH ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 2019.ONCOMED - ESTIMATES 2018 OPERATING CASH BURN TO BE LESS THAN $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS.ONCOMED - ‍TO INITIATE PHASE 1B PORTION OF ITS ANTI-TIGIT TRIAL TO STUDY ANTI-TIGIT IN COMBINATION WITH ANTI-PD1 IN FIRST HALF OF 2018​.  Full Article

Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - PERCEPTIVE ADVISORS LLC :PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC <<>>AS OF NOV 6 - SEC FILING.  Full Article

Oncomed posts Q3 loss per share $0.28
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article

BRIEF-Oncomed Reports Q1 Loss Per Share $0.15

* ONCOMED ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS